questions the common wisdom that intellectual property is the
lifeblood of life sciences needs
only look at two recent examples.
The U.S. Constitution provides authors and inventors with the ability to assert exclusive use of their intellectual property, which includes patents, copyrights, trademarks and trade secrets. The common wisdom is that those being asked to invest in the development of a drug demand that exclusivity to have a better assurance that they will recover their investment.
the White House has proposed a $1 billion initiative to jump-start the effort.
But, given that estimates for the average cost of developing a drug range from
$4 billion to $11 billion, additional
investment surely will be needed.
That is why a prominent attorney and blogger caused some stir
when he suggested that, given recent Supreme Court decisions that have found
natural products of the body to be patent ineligible, fast-tracked cancer
immunotherapy claims could face rejections by patent examiners.
Some attorneys agreed, others disagreed, and I wrote an article about it for Bloomberg BNA that you can find here.
The other example that has turned up is related to the
controversy concerning Mylan’s EpiPen, a medical
device for injecting a measured dose or doses of epinephrine for the
treatment of severe allergic reactions. Consumers and members of Congress have complained that the
price of the EpiPen, which can provide lifesaving
treatment, has jumped tremendously over the past few years.
But a UK blog noted that an interesting side-effect of what is otherwise unwarranted criticism for Mylan is that it enhances the value of its EpiPen trademark. A Bloomberg Business Week 2015 article described how Mylan expanded name recognition for the EpiPen through clever branding and public awareness campaigns. And now the controversy concerning the price of the EpiPen hinges on the fact that it is, for now, the dominant product on the market with an 85 percent market share, which can only enhance the value of its trademark by having physicians and consumers think only of Mylan’s product for a pen treating allergic reactions.
So, even when things might appear to look gloomy, the intellectual property train just keeps chugging along.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)